Investor Relations

Who is BrainsWay?

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.

The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction.

BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Latest Releases

June 8, 2021

BrainsWay to Present at the Raymond James Human Health Innovation Conference

CRESSKILL, N.J. and JERUSALEM, June 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and

Read More

June 7, 2021

BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate

CRESSKILL, N.J. and JERUSALEM, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming

Read More

June 2, 2021

BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield® Licensee HCSC

HCSC Covers Approximately 17 Million Members Across Five States CRESSKILL, N.J. and JERUSALEM, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health

Read More

For more information please contact:

Tel: +1-844-386-7001
Tel: +972-2-647-6010
Email: ir@brainsway.com